Efficacy of disease-modifying therapies in primary progressive multiple sclerosis: systematic review and network meta-analysis
- Journal
- Multiple sclerosis and related disorders (Q1)
- Published
- 10 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Yeray Reyes-de-la-Mata, Gala Cano-Martinez, Emilio Jesus Alegre-Del-Rey, Silvia Fenix-Caballero
- PMID
- 43035027
- DOI
- 10.1016/j.msard.2026.108056
Why clinicians should know about it
- Picked for Neurology (clinical) (paper of the day, 17 November 2026): Network meta-analysis compares disease-modifying therapies in PPMS
Abstract
BACKGROUND: Primary progressive multiple sclerosis (PPMS) leads to continuous neurodegeneration. Treatment options are limited, but B-cell-depleting therapies and brain-penetrant Bruton's tyrosine kinase (BTK) inhibitors have emerged. OBJECTIVES: Compare the efficacy of disease-modifying therapies (DMTs) on 12-week composite confirmed disability progression (cCDP12) in PPMS. Systematic review and Bayesian network meta-analysis of Phase III randomized trials (up to June 2026). Binomial likelihood models estimated odds ratios (OR) and 95% credible intervals (CrI). RESULTS: Five trials (4306 patients) were included. Fenebrutinib (OR 0.52, 95% CrI 0.37-0.72; estimated absolute risk reduction [ARR] = 14.1%, number needed to treat [NNT] = 7), standard ocrelizumab 600 mg (OR 0.71, 95% CrI 0.57-0.87; ARR = 7.8%, NNT = 13), and high-dose ocrelizumab (OR 0.65, 95% CrI 0.45-0.94; ARR = 9.6%, NNT = 11) significantly reduced cCDP12 risk versus placebo. Fingolimod was not effective (OR 0.98, 95% CrI 0.73-1.33). In indirect network comparisons under fixed-effects assumptions, fenebrutinib demonstrated lower odds of cCDP12 relative to standard ocrelizumab (OR 0.73, 95% CrI 0.57-0.95), whereas direct head-to-head trial data from FENtrepid demonstrated comparable primary efficacy / non-inferiority. Under a random-effects sensitivity model, credible intervals widened and crossed 1.00 (OR 0.73, 95% CrI 0.40-1.38), reflecting structural uncertainty in a sparse network. CONCLUSION: Fenebrutinib and ocrelizumab (standard and high-dose) show efficacy in reducing cCDP12 in PPMS. Fenebrutinib demonstrated lower estimated odds of progression under fixed-effects network assumptions, highlighting the clinical potential of central microglial BTK inhibition; however, equivalent direct trial efficacy, loss of statistical significance under random-effects modeling, and baseline clinical heterogeneity (gadolinium-enhancing lesion activity) across trials mandate cautious clinical interpretation. TRIAL REGISTRATION: ClinicalTrials.gov: ORATORIO (NCT01194570); ORATORIOHAND (NCT04035005); GAVOTTE (NCT04548999); FENtrepid (NCT04544449); INFORMS (NCT00731692).
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.